Allarity ended the quarter with $29.8 million in cash and restricted cash, up from $27.7 million year-over-year, and reduced net loss per share to $0.17 from $0.25. R&D expenses held at $1.3 million and G&A at $1.4 million, while the company repurchased shares under its buyback program to enhance capital efficiency.

The company advanced stenoparib development with FDA Fast Track designation for an advanced ovarian cancer Phase 2 trial and opened enrollment in a VA-funded Phase 2 relapsed small cell lung cancer study. Active pharmaceutical ingredient manufacturing for Phase 3-ready production remains on schedule for Q3 2026 with no additional cash outlays anticipated.

Subsequent to quarter-end, a US Notice of Allowance was received for the stenoparib-specific DRP® companion diagnostic patent application. Once issued, the patent is expected to extend drug exclusivity by at least 11 years when used in concert with the DRP® test.

During Q1, Allarity secured a $20 million promissory note financing and established a $6 million equity line of credit to bolster its balance sheet. These financings are earmarked to support ongoing clinical programs, API manufacturing campaigns and corporate operations.